Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
A multi-institution team of lung cancer experts have received a new SU2C grant to bring technology-enabled immunotherapy monitoring to under-represented patients.
A new study by Iok In Christine Chio, PhD, provides key insights towards a possible treatment that can toggle this molecular switch to block the spread of pancreatic cancer to other organs.
New research from the lab of Dennis Vitkup, PhD, reveals reasons why cancer cells are often forced to rely on fat imports, a finding that could lead to new ways to understand and slow tumor growth.
"In the next wave of precision medicine, treating cancer will depend on our ability to be even more predictive with our approaches," writes Dr. Andrea Califano in our latest Disruptors column.
At ASCO 2022, Dr. Catherine Shu shared updated results from a trial of a combination therapy for patients with EGFR mutated non-small cell lung cancer.
Congratulations to Dr. Vasan, one of four physician-scientists named a Gerstner Scholar. This recognition gives early-career scientists vital funding to conduct pioneering research.
The lack of diversity, equity and inclusion in the cancer field remains a problem. With the establishment of the HICCC’s DEI office, there is a reinforced commitment to enact real change and progress.
Many situations, such as post-surgical pain, still require opioids for effective pain management. Unfortunately, any opioid prescription puts patients and their communities at risk for opioid misuse.
A study, led by Dr. Dawn Hershman, tested whether standing orders embedded in electronic medical records systems could improve prescribing practice for CSFs and lower incidence of febrile neutropenia.
